ライフサイエンスコーパス: progression-free survival rate

1 t Milan criteria provides a high local tumor progression-free survival rate.

2 response rate and the 20-week immune-related progression-free survival rate.

3 mide backbone and has promising response and progression-free survival rates.

4 Actual progression-free survival rates 10 years after radical p

5 rate, 71% [5 of 7 patients]; immune-related progression-free survival rate, 67% [4 of 6 patients]).

6 The absolute difference in the 3-year progression-free survival rate (ABVD minus AVD) was 1.6

7 The primary end point was the progression-free survival rate after 6 months (PFS-6).

8 The 4-year overall and progression-free survival rates after UCB transplantatio

9 e improved overall radiographic response and progression-free survival rates, although the impact of

10 l patients with high-risk NMIBC, the 10-year progression-free survival rate and disease-specific deat

11 a median follow-up of 41 months, the 3-year progression-free survival rate and overall survival rate

12 time of 42 months, the estimated overall and progression-free survival rates are 68% and 42%, respect

13 with a positive and negative TSE score show progression free survival rates at 6 months of 67 and 0%

14 , does one have a well-documented historical progression-free survival rate at 1 year for comparison

15 l response after induction and difference in progression-free survival rate at 2 years from randomisa

16 Progression-free survival rate at 2 years was 52.4%.

17 Progression-free survival rate at 36 months after R-CHOP

18 The progression-free survival rate at 36 months was 58%.

19 The progression-free survival rates at 12 months were 43.6%,

20 Estimated progression-free survival rates at 24 months were 51% an

21 Progression-free survival rates at 6 months were 41.8% a

22 Cumulative survival and progression-free survival rates at more than 4.5 years w

23 ary outcome was the difference in the 3-year progression-free survival rate between randomized groups

24 Progression-free survival rates between arms for all ran

25 The 5-year progression-free survival rate for patients with depth o

26 However, the progression-free survival rate for the CRPC patients on

27 The 2- and 5-year progression-free survival rates for all 49 patients trea

28 rable 3-year response, overall survival, and progression-free survival rates for asymptomatic patient

29 f 33 months (range,17-94 months), the 3-year progression-free survival rates for patients with chemor

30 At a median follow-up time of 3.2 years, progression-free survival rates for the IMPT group were

31 zard ratio [HR] 1.05; 95% CI 0.95-1.17), and progression free survival rates (HR 1.01; 95% CI, 0.92-1

32 Progression-free survival rate in the low-risk children

33 more percentage points from the assumed 95% progression-free survival rate in the radiotherapy group

34 ear overall survival rate is 76%, the 3-year progression-free survival rate is 56%, and the 3-year lo

35 The overall survival and progression-free survival rates observed in this trial a

36 e survival time was 13 months, with a 2-year progression-free survival rate of 26.4%.

37 all objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overal

38 ulting in a 63% durable CR rate and a 2-year progression-free survival rate of 65% (95% CI, 51% to 79

39 signed to exclude a difference in the 3-year progression-free survival rate of 7 or more percentage p

40 l (24 from Hodgkin's lymphoma), for a 3-year progression-free survival rate of 82.6% and an overall s

41 ival rate of 98% (95% CI 92-99) and a 5-year progression-free survival rate of 83% (76-88) for supram

42 A 1-year progression-free survival rate of greater than 60% was r

43 5.9 years (range, 0.5-10 years), the 6-year progression-free survival rate of patients who underwent

44 -84) versus 48% (29-65; p<0.0001) and 5-year progression-free survival rates of 44% (38-50) versus 25

45 had disease progression or died, with 2-year progression-free survival rates of 69 and 55%, respectiv

46 , with estimated 3-year overall survival and progression-free survival rates of 73% (95% confidence i

47 rates of 87%, 64%, 53%, and 22%, and 5-year progression-free survival rates of 83%, 55%, 33%, and 12

48 Progression-free survival rates of patients who underwen

49 Secondary outcomes were progression-free survival; rates of grade 3 or 4 adverse

50 (22% v 11%; P = .034), but decreased 3-year progression-free survival rates (P < .0001) and 3-year o

51 nsplantation for both overall (P = .001) and progression-free survival rates (P < .001).

52 included objective response rate and 24-week progression-free survival rate (per Response Evaluation

53 response rate, complete remission (CR) rate, progression-free survival rate (PFS), and OS.

54 The primary end point was progression-free survival rate (PFSR) at 12 weeks; secon

55 ts compared with historical series; however, progression-free survival rates remain disappointing, ra

56 and bevacizumab achieved better overall and progression-free survival rates than sorafenib in unrese

57 abine-docetaxel was associated with a 2-year progression-free survival rate that appears superior to

58 ndpoint versus the historical control 1-year progression-free survival rate used to determine the sam

59 The 6-month progression-free survival rate was 10% (95% CI, 2% to 26

60 nths (95% CI, 1.8 to 2.1 months) and 4-month progression-free survival rate was 13% +/- 5%.

61 The 5-year progression-free survival rate was 21% +/- 8%.

62 The 6-month progression-free survival rate was 32% (95% CI, 14% to 5

63 The 1-year progression-free survival rate was 34.8% (95% CI, 16.6%-

64 The 2-year progression-free survival rate was 57% (95% CI, 33%-75%)

65 t a median follow-up of 370 days, the 1-year progression-free survival rate was 58.2% (95% CI, 33.1%-

66 After 18 months, the progression-free survival rate was 63.0% (95% confidence

67 The overall progression-free survival rate was 67% (95%, CI: 61%-73%

68 findings on a third PET-CT scan; the 3-year progression-free survival rate was 67.5% and the overall

69 The progression-free survival rate was 69% at 24 weeks and 4

70 The 6-month progression-free survival rate was 7.7% for the glioblas

71 The 3-month progression-free survival rate was 71.1% (95% CI, 60.5%

72 median follow-up of 23 months, the 36-month progression-free survival rate was 72%.

73 In the U.S. trial, at 1 year, the progression-free survival rate was 73% and the overall s

74 At 26 months, the estimated progression-free survival rate was 75% and the rate of o

75 1 to 21.2 months), and the estimated 1-year progression-free survival rate was 8%.

76 The estimated 4-year progression-free survival rate was 85.5% (97.5% CI 79.9-

77 ad a major response), the estimated 18 month progression-free survival rate was 86% (95% CI 66-94), a

78 24.2 months (95% CI, 23.4-26.9), the 2-year progression-free survival rate was 88% (95% CI, 75.7-94.

79 6.6 years (range, 0.1-12 years), the 6-year progression-free survival rate was 88% (95% confidence i

80 At cycle 31, the progression-free survival rate was 89.9%.

81 The 18-month progression-free survival rate was 90.5% (95% CI, 67.0 t

82 One-year progression-free survival rate was 91%.

83 The 3-year progression-free survival rate was 94.6% (95% confidence

84 e of 25 months, the estimated 3-year current progression-free survival rate was 95%.

85 e was 196 months (16.3 years) and the median progression-free survival rate was 98 months (8.2 years)

86 The progression-free survival rate was better after a comple

87 Progression-free survival rate was the same after lobect

88 d objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patient

89 Three-year progression-free survival rates were 14% versus 1%, and

90 The progression-free survival rates were 21% (95% confidence

91 The median overall and progression-free survival rates were 28 and 14 months, r

92 Twelve-month progression-free survival rates were 35% (95% CI, 31%-39

93 ab-plus-irinotecan groups, estimated 6-month progression-free survival rates were 42.6% and 50.3%, re

94 lts The 8-year time to treatment failure and progression-free survival rates were 44% (95% CI, 39% to

95 Three- and 6-month progression-free survival rates were 47% and 33% for cho

96 3%, 47%, 47%, and 43%, respectively; 24-week progression-free survival rates were 51%, 71%, 38%, and

97 The estimated 6-, 12-, and 18-month progression-free survival rates were 51.3% (90% CI, 38.2

98 The estimated 3-year overall and progression-free survival rates were 59% and 51%, respec

99 The 2-year progression-free survival rates were 63% (95% CI, 49% to

100 The 1-, 2-, and 3- year progression-free survival rates were 70%, 57%, and 50%,

101 One- and five-year progression-free survival rates were 71% and 48%, respec

102 fter a median follow-up of 67 months, 5-year progression-free survival rates were 72% in the inductio

103 14 [95% CI 0.138-0.334]; p<0.0001); 42-month progression-free survival rates were 74.6% (95% CI 65.0-

104 months, respectively; the 1-year overall and progression-free survival rates were 76% and 59%, respec

105 Their 3-year progression-free survival rates were 78%, 33%, and 0%, r

106 42 months), the 11-year overall survival and progression-free survival rates were 78%, and 72%, respe

107 5-year progression-free survival rates were 81% (95% CI 71-87)

108 The 1-year overall and progression-free survival rates were 82% and 73%, respec

109 The overall 5- and 7-year progression-free survival rates were 82% and 80%, respec

110 w-up of 28.9 months, estimated 1- and 2-year progression-free survival rates were 84.1% and 78.6%, re

111 s (range, 19-94), the estimated survival and progression-free survival rates were 85% and 83%, respec

112 With a median follow-up of 23 months, 2-year progression-free survival rates were 86% for interim PET

113 or pembrolizumab and 10.1% for chemotherapy; progression-free survival rates were 9.5% and 2.7%, resp

114 The estimated 10-year progression-free survival rates were 9.5% and 9.2% for t

115 (range, 6-50 months), the 2-year overall and progression-free survival rates were 90% and 75%.

116 he RVd group progressed; respective 24-month progression-free survival rates were 95.8% and 89.8%.

117 r-month actuarial overall and local-regional progression-free survival rates were both 50%.

118 The overall progression-free survival rates were similar between the

119 The estimated 6-month progression-free-survival rates were 47.3% for pembroliz

120 The primary end point was 6-mo progression-free survival rate, which was 74% (95% CI: 5